Ataluren treatment of patients with nonsense mutation dystrophinopathy

Katharine Bushby, Richard Finkel, Brenda Wong, Richard Barohn, Craig Campbell, Giacomo P. Comi, Anne M. Connolly, John W. Day, Kevin M. Flanigan, Nathalie Goemans, Kristi J. Jones, Eugenio Mercuri, Ros Quinlivan, James B. Renfroe, Barry Russman, Monique M. Ryan, Mar Tulinius, Thomas Voit, Steven A. Moore, H. Lee SweeneyRichard T. Abresch, Kim L. Coleman, Michelle Eagle, Julaine Florence, Eduard Gappmaier, Allan M. Glanzman, Erik Henricson, Jay Barth, Gary L. Elfring, Allen Reha, Robert J. Spiegel, Michael W. O'donnell, Stuart W. Peltz, Craig M. Mcdonald

Research output: Contribution to journalArticle

Abstract

Introduction: Dystrophinopathy is a rare, severe muscle disorder, and nonsense mutations are found in 13% of cases. Ataluren was developed to enable ribosomal readthrough of premature stop codons in nonsense mutation (nm) genetic disorders. Methods: Randomized, double-blind, placebo-controlled study; males ≥5 years with nm-dystrophinopathy received study drug orally 3 times daily, ataluren 10, 10, 20 mg/kg (N=57); ataluren 20, 20, 40 mg/kg (N=60); or placebo (N=57) for 48 weeks. The primary endpoint was change in 6-Minute Walk Distance (6MWD) at Week 48. Results: Ataluren was generally well tolerated. The primary endpoint favored ataluren 10, 10, 20 mg/kg versus placebo; the week 48 6MWD Δ=31.3 meters, post hoc P=0.056. Secondary endpoints (timed function tests) showed meaningful differences between ataluren 10, 10, 20 mg/kg, and placebo. Conclusions: As the first investigational new drug targeting the underlying cause of nm-dystrophinopathy, ataluren offers promise as a treatment for this orphan genetic disorder with high unmet medical need.

Original languageEnglish
Pages (from-to)477-487
Number of pages11
JournalMuscle and Nerve
Volume50
Issue number4
DOIs
Publication statusPublished - Oct 1 2014

Fingerprint

Nonsense Codon
Placebos
Inborn Genetic Diseases
Therapeutics
Investigational Drugs
Orphaned Children
Muscular Diseases
Drug Delivery Systems
ataluren
Double-Blind Method
Pharmaceutical Preparations

Keywords

  • Duchenne muscular dystrophy
  • Genetic
  • Nonsense mutation
  • Orphan
  • Pediatric

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)
  • Physiology

Cite this

Bushby, K., Finkel, R., Wong, B., Barohn, R., Campbell, C., Comi, G. P., ... Mcdonald, C. M. (2014). Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle and Nerve, 50(4), 477-487. https://doi.org/10.1002/mus.24332

Ataluren treatment of patients with nonsense mutation dystrophinopathy. / Bushby, Katharine; Finkel, Richard; Wong, Brenda; Barohn, Richard; Campbell, Craig; Comi, Giacomo P.; Connolly, Anne M.; Day, John W.; Flanigan, Kevin M.; Goemans, Nathalie; Jones, Kristi J.; Mercuri, Eugenio; Quinlivan, Ros; Renfroe, James B.; Russman, Barry; Ryan, Monique M.; Tulinius, Mar; Voit, Thomas; Moore, Steven A.; Lee Sweeney, H.; Abresch, Richard T.; Coleman, Kim L.; Eagle, Michelle; Florence, Julaine; Gappmaier, Eduard; Glanzman, Allan M.; Henricson, Erik; Barth, Jay; Elfring, Gary L.; Reha, Allen; Spiegel, Robert J.; O'donnell, Michael W.; Peltz, Stuart W.; Mcdonald, Craig M.

In: Muscle and Nerve, Vol. 50, No. 4, 01.10.2014, p. 477-487.

Research output: Contribution to journalArticle

Bushby, K, Finkel, R, Wong, B, Barohn, R, Campbell, C, Comi, GP, Connolly, AM, Day, JW, Flanigan, KM, Goemans, N, Jones, KJ, Mercuri, E, Quinlivan, R, Renfroe, JB, Russman, B, Ryan, MM, Tulinius, M, Voit, T, Moore, SA, Lee Sweeney, H, Abresch, RT, Coleman, KL, Eagle, M, Florence, J, Gappmaier, E, Glanzman, AM, Henricson, E, Barth, J, Elfring, GL, Reha, A, Spiegel, RJ, O'donnell, MW, Peltz, SW & Mcdonald, CM 2014, 'Ataluren treatment of patients with nonsense mutation dystrophinopathy', Muscle and Nerve, vol. 50, no. 4, pp. 477-487. https://doi.org/10.1002/mus.24332
Bushby K, Finkel R, Wong B, Barohn R, Campbell C, Comi GP et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle and Nerve. 2014 Oct 1;50(4):477-487. https://doi.org/10.1002/mus.24332
Bushby, Katharine ; Finkel, Richard ; Wong, Brenda ; Barohn, Richard ; Campbell, Craig ; Comi, Giacomo P. ; Connolly, Anne M. ; Day, John W. ; Flanigan, Kevin M. ; Goemans, Nathalie ; Jones, Kristi J. ; Mercuri, Eugenio ; Quinlivan, Ros ; Renfroe, James B. ; Russman, Barry ; Ryan, Monique M. ; Tulinius, Mar ; Voit, Thomas ; Moore, Steven A. ; Lee Sweeney, H. ; Abresch, Richard T. ; Coleman, Kim L. ; Eagle, Michelle ; Florence, Julaine ; Gappmaier, Eduard ; Glanzman, Allan M. ; Henricson, Erik ; Barth, Jay ; Elfring, Gary L. ; Reha, Allen ; Spiegel, Robert J. ; O'donnell, Michael W. ; Peltz, Stuart W. ; Mcdonald, Craig M. / Ataluren treatment of patients with nonsense mutation dystrophinopathy. In: Muscle and Nerve. 2014 ; Vol. 50, No. 4. pp. 477-487.
@article{625ccc4e2b034c87a97dcd590ed8d21c,
title = "Ataluren treatment of patients with nonsense mutation dystrophinopathy",
abstract = "Introduction: Dystrophinopathy is a rare, severe muscle disorder, and nonsense mutations are found in 13{\%} of cases. Ataluren was developed to enable ribosomal readthrough of premature stop codons in nonsense mutation (nm) genetic disorders. Methods: Randomized, double-blind, placebo-controlled study; males ≥5 years with nm-dystrophinopathy received study drug orally 3 times daily, ataluren 10, 10, 20 mg/kg (N=57); ataluren 20, 20, 40 mg/kg (N=60); or placebo (N=57) for 48 weeks. The primary endpoint was change in 6-Minute Walk Distance (6MWD) at Week 48. Results: Ataluren was generally well tolerated. The primary endpoint favored ataluren 10, 10, 20 mg/kg versus placebo; the week 48 6MWD Δ=31.3 meters, post hoc P=0.056. Secondary endpoints (timed function tests) showed meaningful differences between ataluren 10, 10, 20 mg/kg, and placebo. Conclusions: As the first investigational new drug targeting the underlying cause of nm-dystrophinopathy, ataluren offers promise as a treatment for this orphan genetic disorder with high unmet medical need.",
keywords = "Duchenne muscular dystrophy, Genetic, Nonsense mutation, Orphan, Pediatric",
author = "Katharine Bushby and Richard Finkel and Brenda Wong and Richard Barohn and Craig Campbell and Comi, {Giacomo P.} and Connolly, {Anne M.} and Day, {John W.} and Flanigan, {Kevin M.} and Nathalie Goemans and Jones, {Kristi J.} and Eugenio Mercuri and Ros Quinlivan and Renfroe, {James B.} and Barry Russman and Ryan, {Monique M.} and Mar Tulinius and Thomas Voit and Moore, {Steven A.} and {Lee Sweeney}, H. and Abresch, {Richard T.} and Coleman, {Kim L.} and Michelle Eagle and Julaine Florence and Eduard Gappmaier and Glanzman, {Allan M.} and Erik Henricson and Jay Barth and Elfring, {Gary L.} and Allen Reha and Spiegel, {Robert J.} and O'donnell, {Michael W.} and Peltz, {Stuart W.} and Mcdonald, {Craig M.}",
year = "2014",
month = "10",
day = "1",
doi = "10.1002/mus.24332",
language = "English",
volume = "50",
pages = "477--487",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Ataluren treatment of patients with nonsense mutation dystrophinopathy

AU - Bushby, Katharine

AU - Finkel, Richard

AU - Wong, Brenda

AU - Barohn, Richard

AU - Campbell, Craig

AU - Comi, Giacomo P.

AU - Connolly, Anne M.

AU - Day, John W.

AU - Flanigan, Kevin M.

AU - Goemans, Nathalie

AU - Jones, Kristi J.

AU - Mercuri, Eugenio

AU - Quinlivan, Ros

AU - Renfroe, James B.

AU - Russman, Barry

AU - Ryan, Monique M.

AU - Tulinius, Mar

AU - Voit, Thomas

AU - Moore, Steven A.

AU - Lee Sweeney, H.

AU - Abresch, Richard T.

AU - Coleman, Kim L.

AU - Eagle, Michelle

AU - Florence, Julaine

AU - Gappmaier, Eduard

AU - Glanzman, Allan M.

AU - Henricson, Erik

AU - Barth, Jay

AU - Elfring, Gary L.

AU - Reha, Allen

AU - Spiegel, Robert J.

AU - O'donnell, Michael W.

AU - Peltz, Stuart W.

AU - Mcdonald, Craig M.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Introduction: Dystrophinopathy is a rare, severe muscle disorder, and nonsense mutations are found in 13% of cases. Ataluren was developed to enable ribosomal readthrough of premature stop codons in nonsense mutation (nm) genetic disorders. Methods: Randomized, double-blind, placebo-controlled study; males ≥5 years with nm-dystrophinopathy received study drug orally 3 times daily, ataluren 10, 10, 20 mg/kg (N=57); ataluren 20, 20, 40 mg/kg (N=60); or placebo (N=57) for 48 weeks. The primary endpoint was change in 6-Minute Walk Distance (6MWD) at Week 48. Results: Ataluren was generally well tolerated. The primary endpoint favored ataluren 10, 10, 20 mg/kg versus placebo; the week 48 6MWD Δ=31.3 meters, post hoc P=0.056. Secondary endpoints (timed function tests) showed meaningful differences between ataluren 10, 10, 20 mg/kg, and placebo. Conclusions: As the first investigational new drug targeting the underlying cause of nm-dystrophinopathy, ataluren offers promise as a treatment for this orphan genetic disorder with high unmet medical need.

AB - Introduction: Dystrophinopathy is a rare, severe muscle disorder, and nonsense mutations are found in 13% of cases. Ataluren was developed to enable ribosomal readthrough of premature stop codons in nonsense mutation (nm) genetic disorders. Methods: Randomized, double-blind, placebo-controlled study; males ≥5 years with nm-dystrophinopathy received study drug orally 3 times daily, ataluren 10, 10, 20 mg/kg (N=57); ataluren 20, 20, 40 mg/kg (N=60); or placebo (N=57) for 48 weeks. The primary endpoint was change in 6-Minute Walk Distance (6MWD) at Week 48. Results: Ataluren was generally well tolerated. The primary endpoint favored ataluren 10, 10, 20 mg/kg versus placebo; the week 48 6MWD Δ=31.3 meters, post hoc P=0.056. Secondary endpoints (timed function tests) showed meaningful differences between ataluren 10, 10, 20 mg/kg, and placebo. Conclusions: As the first investigational new drug targeting the underlying cause of nm-dystrophinopathy, ataluren offers promise as a treatment for this orphan genetic disorder with high unmet medical need.

KW - Duchenne muscular dystrophy

KW - Genetic

KW - Nonsense mutation

KW - Orphan

KW - Pediatric

UR - http://www.scopus.com/inward/record.url?scp=84927669185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927669185&partnerID=8YFLogxK

U2 - 10.1002/mus.24332

DO - 10.1002/mus.24332

M3 - Article

C2 - 25042182

AN - SCOPUS:84927669185

VL - 50

SP - 477

EP - 487

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

IS - 4

ER -